Page 84 - 2018_11-Haematologica-web

T. Toya et al.
prognostic value of age and digestive involvement. The CRP level at onset also predicts the patients’ survival, per- haps reflecting the importance of the inflammatory status in the ECD condition. Additional large-scale studies are required in order to clarify the pathophysiology of ECD and improve the prognosis of the patients.
Acknowledgments
We would like to acknowledge K. Tanaka and Y. Nakada for their technical assistance.
Furthermore, we thank M. Fukuda (Asoka Hospital), H. Hiraga (Hokkaido Cancer Center), T. Yamauchi (Toki General Hospital), K. Takeuchi (Tochigi Cancer Center), Y. Shido (Hamamatsu University School of Medicine), S. Nogawa (Tokyo Dental College Ichikawa General Hospital), T. Hamada (Okayama University), N. Hayashi (Wakayama Rosai Hospital), S. Yokokura (Shin-Yamanote Hospital), T. Makiishi (Japanese Red Cross Otsu Hospital), T. Kitani (Ehime University), Y. Shibuya (Showa University Northern Yokohama Hospital), M. Yoshimitsu (Kagoshima University), J. Mitsushima (Matsue Seikyo General Hospital), S. Yano (Matsue Medical
Hospital), K. Tanaka (Okayama University), M. Yamamoto (Kochi University), K. Sato (Saitama Medical University), H. Sugano (Kochi Health Sciences Center), T. Kondo (Kyoto University), H. Takahama (National Cerebral and Cardiovascular Center), J. Nagano (Seirei Hamamatsu General Hospital), T. Baba (Kanagawa Cardiovascular and Respiratory Center), Y. Fukui (Juntendo University), K. Takenaka (Tsuchiura Kyodo General Hospital), K. Takada (Sapporo Medical University), S. Izumi (National Center for Global Health and Medicine), J. Kikuchi (Keio University), K. Takahashi (Kameda Medical Center), K. Shimizu (Higashihiroshima Medical Center), K. Takemura (Tokyo Teishin Hospital), and I. Choi (National Hospital Organization Kyushu Cancer Center) for pro- viding the clinical data and/or patient samples. We also thank H. Kawano (Teikyo University) and the members of the Japanese Musculoskeletal Oncology Group for cooperating in the collection of clinical data and/or patient samples.
Funding
This study is supported by Grants-in-Aid of the Ministry of Health, Labor and Welfare of Japan (H28-Nanchi-Ippan-002 to MS, TO, IK, and MK).
Center), M. Susa (Keio University), K. Ono
(Tosei General
References
1. Chester W. Uber lipoidgranulomatose. Virchows Arch Pathol Anat 1930;279:561- 602.
2. Haroche J, Abla O. Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xan- thogranuloma, and Erdheim-Chester dis- ease. Hematology Am Soc Hematol Educ Program. 2015;2015:571-578.
3. Haroche J, Cohen-Aubart F, Charlotte F, et al. The histiocytosis Erdheim-Chester dis- ease is an inflammatory myeloid neoplasm. Expert Rev Clin Immunol. 2015;11(9):1033- 1042.
4. HarocheJ,Cohen-AubartF,RollinsBJ,etal. Histiocytoses: emerging neoplasia behind inflammation. Lancet Oncol. 2017; 18(2):e113-e125.
5. Diamond EL, Dagna L, Hyman DM, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014;124(4):483-492.
6. Estrada-VerasJI,O'BrienKJ,BoydLC,etal. The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv. 2017;1(6):357-366.
7. Cavalli G, Guglielmi B, Berti A, Campochiaro C, Sabbadini MG, Dagna L. The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis. 2013; 72(10):1691-1695.
8. Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim- Chester disease and Langerhans cell histio- cytosis harboring the BRAF V600E muta- tion. Blood. 2013;121(9):1495-1500.
9. HarocheJ,CharlotteF,ArnaudL,etal.High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120(13):2700-2703.
10. EmileJF,DiamondEL,Helias-RodzewiczZ, et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood. 2014; 124(19):3016-3019.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
Milne P, Bigley V, Bacon CM, et al. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim Chester disease in adults. Blood. 2017;130(2):167-175. Berres ML, Merad M, Allen CE. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to histi- ocytosis X? Br J Haematol. 2015;169(1):3- 13.
Durham BH, Roos-Weil D, Baillou C, et al. Functional evidence for derivation of sys- temic histiocytic neoplasms from hematopoietic stem/progenitor cells. Blood. 2017;130(2):176-180.
Reproducible and sustained efficacy of tar- geted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim- Chester disease. J Clin Oncol. 2015; 33(5):411-418.
22. Haroche J, Amoura Z, Trad SG, et al. Variability in the efficacy of interferon- alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum. 2006; 54(10):3330-3336.
23. Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005;19(2):105-
Cavalli G, Biavasco R, Borgiani B, Dagna L. Oncogene-induced senescence as a new 123.
mechanism of disease: the paradigm of erd- heim-chester disease. Front Immunol. 2014;5:281.
Cangi MG, Biavasco R, Cavalli G, et al. BRAFV600E-mutation is invariably present and associated to oncogene-induced senes- cence in Erdheim-Chester disease. Ann Rheum Dis. 2015;74(8):1596-1602.
Arnaud L, Hervier B, Neel A, et al. CNS involvement and treatment with interfer- on-alpha are independent prognostic fac- tors in Erdheim-Chester disease: a multi- center survival analysis of 53 patients. Blood. 2011;117(10):2778-2782.
Cohen Aubart F, Emile JF, Carrat F, et al. Targeted therapies in 54 patients with Erdheim-Chester disease, including follow- up after interruption (the LOVE study). Blood. 2017;130(11):1377-1380.
Arcaini L, Zibellini S, Boveri E, et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neo- plasms. Blood. 2012;119(1):188-191.
Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neo- plasms of the macrophage-dendritic cell lin- eages. Blood. 2016;127(22):2672-2681. Haroche J, Amoura Z, Dion E, et al. Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review. Medicine (Baltimore). 2004;83(6):371-392. Haroche J, Cohen-Aubart F, Emile JF, et al.
24. Hervier B, Haroche J, Arnaud L, et al. Association of both Langerhans cell histio- cytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood. 2014; 124(7):1119-1126.
25. Arnaud L, Gorochov G, Charlotte F, et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood. 2011;117(10):2783-2790.
26. Berti A, Cavalli G, Guglielmi B, et al. Tocilizumab in patients with multisystem Erdheim-Chester disease. Oncoimmunology. 2017;6(6):e1318237.
27. Dagna L, Corti A, Langheim S, et al. Tumor necrosis factor alpha as a master regulator of inflammation in Erdheim-Chester dis- ease: rationale for the treatment of patients with infliximab. J Clin Oncol. 2012; 30(28):e286-290.
28. Aouba A, Georgin-Lavialle S, Pagnoux C, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood. 2010;116(20):4070-4076.
29. Papo M, Diamond EL, Cohen-Aubart F, et al. High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocy- tosis. Blood. 2017;130(8):1007-1013.
30. Drier A, Haroche J, Savatovsky J, et al. Cerebral, facial, and orbital involvement in Erdheim-Chester disease: CT and MR imaging findings. Radiology. 2010; 255(2):586-594.
1824
haematologica | 2018; 103(11)